Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Janice Shell who wrote (2302)	7/1/1998 10:45:00 AM
From: Prospector	Read Replies (2) \| Respond to of 5402

Here comes Peter cotton tail hoppin down the Bunny trail... Prospector (hahahaha)

To: Janice Shell who wrote (2302)	7/1/1998 12:57:00 PM
From: dwlima	Respond to of 5402

wow! i just got back from my meeting and saw the low for the day....it is amazing how much money i lost this morning and then recuperated- and i did not even know. and Janice, you are right...there is more than meets the eye here. my guess is that there were a lot of limit orders placed and the MMs dropped the bid the scoop them up and kept the ask the same to keep the volume and buying down. Looks like covering to me. anyway, i thought the huge 20%+ spread merited some additional thoughts and insights. well, thank goodness we are back to a better price dwlima

To: Janice Shell who wrote (2302)	7/1/1998 1:00:00 PM
From: dwlima	Read Replies (1) \| Respond to of 5402

yahoo has a low of 67-cents and thompson realtime says 37-cents! any ideas...well, i guess it does not matter anymore....however, this note may shed light on my past message. dwlima

To: Janice Shell who wrote (2302)	7/1/1998 10:33:00 PM
From: chirodoc	Read Replies (1) \| Respond to of 5402

RECENT ANIMAL TESTING WITH PFC'S The first formal report of recent animal testing of our liquid ventilation product, Fluorovent, was presented at the 1995 Hot Topics in Neonatology Conference that was attended by more than 1,000 physicians and scientists from around the world. Fluorovent, made with new fluorocarbon, has a much slower evaporation rate than was previously achievable. This is considered an important selection criteria for a beneficial liquid ventilation product and relates to safety and cost-effectiveness. In addition, Fluorovent did not cause hyperinflated lung syndrome, a toxic side-effect experienced by different fluorocarbons (PFCs). Our studies show that SYBD has developed an improved safer, cost-effective liquid ventilation product. Further animal testing is justified. Dr. Thomas Shaffer, a leading researcher in liquid ventilation, led the liquid ventilation section of the Hot Topics Conference. He noted that early research by Leland C. Clark, Jr. PhD., our Director of Research, was the genesis for today's continuing pursuit of the best PFC for liquid ventilation. Shaffer stated that PFCs have different properties, making some more suitable than others for specific clinical applications. He predicted that future research would match specific applications to "designer PFCs." The only other liquid ventilation product currently under development, LiquiVent (Alliance Pharmaceuticals), has shown some promising results in early clinical testing, but requires continual loading and replacement dosing regimens because of its high evaporation rate, which we believe will increase treatment costs. Stringent bioanalytical controls have made our most recent advances possible. Manufactured specifically for SYBD, Fluorovent is subject to the very highest standards of quality and purity. It is the first fluorocarbon liquid designed and developed for a specific area of critical care medicine. Other PFCs (Decalin-Green Cross of Japan and PFOB-Alliance) were originally made for commercial uses and later adapted for medicine. SYBD has filed patent applications and others are being prepared, all having to do with the use of our new fluorocarbon liquid which will be used to treat various lung diseases including infant and adult respiratory distress, both chronic and acute.